Genes & biomarkers
FGFR3 variants
FGFR3 · urothelial cancer
Relevant to treatment in some advanced urothelial cancers.
Sources checked · Introductory guide
On this page
What does this result mean?
FGFR3 encodes a growth-signaling receptor. Alterations occur in some urothelial cancers, including bladder cancer. Despite similar names, FGFR2 and FGFR3 are separate genes.[1]
How does it connect to treatment?
Erdafitinib is used in selected advanced FGFR3-altered urothelial cancers after progression on systemic therapy. FGFR2 criteria from bile duct cancer do not directly apply.[2]
What should I check in my report?
Confirm the precise qualifying FGFR3 alteration. If treatment is considered, ask about required follow-up, including eye checks and phosphate measurements.
Questions for your care team
- Do my FGFR3 result and prior treatment meet the drug criteria?
- Which treatments or trials fit my cancer type, stage and previous treatment?
Sources and scope
Source documents are in English.
Entries summarize and translate linked official public sources. The source-check date records when those sources were checked; it does not indicate a clinician’s review.
General information based on official public sources. This is not a complete list of uses or side effects. Individual treatment decisions require your care team and current source documents. US-source uses do not establish local approval or reimbursement.